Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
IMTR, Institute of Medical Technology and Research, Rottmersleben, Germany.
Clin Res Cardiol. 2017 Oct;106(10):796-801. doi: 10.1007/s00392-017-1121-2. Epub 2017 May 5.
Cardiac resynchronisation therapy (CRT) is an established treatment option for chronic heart failure patients with left bundle branch block. Although a concomitant functional mitral regurgitation is often reduced by CRT, many patients need additional mitral valve repair. Placing a CARILLON Mitral Contour System (CMCS) over a transvenous CRT lead is currently not recommended, since both of them are implanted in the coronary sinus (CS). The aim of this study was to investigate the feasibility of sequential implantation of a transvenous LV lead followed by CMCS implantation, and to assess LV lead performance and possibility of extraction.
Standard transvenous LV leads were implanted in the CS of five female sheep. After establishing regular anatomical position with stable electrical parameters of the LV lead, a CMCS was additionally implanted in the CS. After an observation period of 100 days, lead performance and positions of lead and CMCS were studied. Sequential implantation of the two components was feasible in sheep. After 100 days, all leads showed regular measurements of impedance, threshold, and sensing. There was no migration of either the LV lead or the CMCS. In all cases, the LV lead could be completely extracted without migration of the CMCS. There were no acute or long-term complications.
In an animal model of healthy adult sheep, implantation of CMCS with a transvenous LV lead already in place was feasible and without major problems with either the CMCS or the LV lead. Electrical performance of the LV leads was excellent. All LV leads could be extracted without migration of the CMCS.
心脏再同步治疗(CRT)是慢性心力衰竭伴左束支传导阻滞患者的一种既定治疗选择。虽然 CRT 通常会减轻同时存在的功能性二尖瓣反流,但许多患者仍需要进行二尖瓣修复。目前不建议将 CARILLON 二尖瓣成形系统(CMCS)放置在经静脉 CRT 导线上,因为两者都植入冠状窦(CS)中。本研究旨在探讨经静脉 LV 导线序贯植入后再植入 CMCS 的可行性,并评估 LV 导线性能和可提取性。
在五只雌性绵羊的 CS 中植入标准的经静脉 LV 导线。在 LV 导线具有稳定的电参数并建立常规解剖位置后,在 CS 中另外植入 CMCS。在 100 天的观察期后,研究了导线性能和导线及 CMCS 的位置。两种组件的序贯植入在绵羊中是可行的。100 天后,所有导线均显示出阻抗、阈值和感知的常规测量值。LV 导线或 CMCS 均无迁移。在所有情况下,LV 导线均可完全提取,而 CMCS 无迁移。无急性或长期并发症。
在健康成年绵羊的动物模型中,CMCS 与已放置的经静脉 LV 导线一起植入是可行的,且 CMCS 和 LV 导线均无重大问题。LV 导线的电性能非常出色。所有 LV 导线均可提取,而 CMCS 无迁移。